Cargando…

Blockers of Skeletal Muscle Na(v)1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back

The voltage-gated sodium channels represent an important target for drug discovery since a large number of physiological processes are regulated by these channels. In several excitability disorders, including epilepsy, cardiac arrhythmias, chronic pain, and non-dystrophic myotonia, blockers of volta...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bellis, Michela, Boccanegra, Brigida, Cerchiara, Alessandro Giovanni, Imbrici, Paola, De Luca, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821513/ https://www.ncbi.nlm.nih.gov/pubmed/36614292 http://dx.doi.org/10.3390/ijms24010857

Ejemplares similares

Searching for novel anti-myotonic agents: Pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide
por: De Luca, Annamaria, et al.
Publicado: (2012)

Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential
por: De Bellis, Michela, et al.
Publicado: (2018)

Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical–Experimental, and Real-World Evidence
por: Crisafulli, Salvatore, et al.
Publicado: (2023)

LKB1 signaling is altered in skeletal muscle of a Duchenne muscular dystrophy mouse model
por: Boccanegra, Brigida, et al.
Publicado: (2023)

Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks
por: Boccanegra, Brigida, et al.
Publicado: (2020)

Toward precision medicine in myotonic syndromes
por: De Bellis, Michela, et al.
Publicado: (2017)

Kinetics of veratridine action on Na channels of skeletal muscle
por: Sutro, JB
Publicado: (1986)

Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy
por: Boccanegra, Brigida, et al.
Publicado: (2023)

Ergogenic Effect of BCAAs and L-Alanine Supplementation: Proof-of-Concept Study in a Murine Model of Physiological Exercise
por: Mantuano, Paola, et al.
Publicado: (2020)

β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation
por: Mantuano, Paola, et al.
Publicado: (2021)

Preclinical Ultrasonography in Rodent Models of Neuromuscular Disorders: The State of the Art for Diagnostic and Therapeutic Applications
por: Mele, Antonietta, et al.
Publicado: (2023)

An Inactivation Stabilizer of the Na(+) Channel Acts as an Opportunistic Pore Blocker Modulated by External Na(+)
por: Yang, Ya-Chin, et al.
Publicado: (2005)

Branched-Chain Amino Acids and Di-Alanine Supplementation in Aged Mice: A Translational Study on Sarcopenia
por: Mantuano, Paola, et al.
Publicado: (2023)

Skeletal Muscle Na(+) Channel Disorders
por: Simkin, Dina, et al.
Publicado: (2011)

Calixmexitil: Calixarene-based Cluster of Mexiletine with Amplified Anti-myotonic Activity as A Novel Use-dependent Sodium Channel Blocker
por: Delnavaz Shahr, Amirali, et al.
Publicado: (2019)

Na channel distribution in vertebrate skeletal muscle
Publicado: (1986)

Sarcoplasmic Reticulum Ca(2+) Buffer Proteins: A Focus on the Yet-To-Be-Explored Role of Sarcalumenin in Skeletal Muscle Health and Disease
por: Conte, Elena, et al.
Publicado: (2023)

Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options
por: Camerino, Giulia Maria, et al.
Publicado: (2019)

Tramadol as a Voltage-Gated Sodium Channel Blocker of Peripheral Sodium Channels Na(v)1.7 and Na(v)1.5
por: Bok, Chan-Su, et al.
Publicado: (2023)

CFTR Channel Pharmacology: Novel Pore Blockers Identified by High-throughput Screening
por: Sheppard, David N.
Publicado: (2004)

Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers
por: Park, Hwan-Woo, et al.
Publicado: (2014)

Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy
por: André, Laurène M., et al.
Publicado: (2018)

Combined pharmacological administration of AQP1 ion channel blocker AqB011 and water channel blocker Bacopaside II amplifies inhibition of colon cancer cell migration
por: De Ieso, Michael L., et al.
Publicado: (2019)

I–J loop involvement in the pharmacological profile of CLC-K channels expressed in Xenopus oocytes
por: Gradogna, Antonella, et al.
Publicado: (2014)

Osteoarthritis-dependent changes in antinociceptive action of Na(v)1.7 and Na(v)1.8 sodium channel blockers: An in vivo electrophysiological study in the rat
por: Rahman, W., et al.
Publicado: (2015)

Functional and Structural Characterization of ClC-1 and Na(v)1.4 Channels Resulting from CLCN1 and SCN4A Mutations Identified Alone and Coexisting in Myotonic Patients
por: Brenes, Oscar, et al.
Publicado: (2021)

Neuroprotective effects of the new Na channel blocker rs100642 in global ischemic brain injury
por: Kamisli, Suat, et al.
Publicado: (2019)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Blocker-related changes of channel density. Analysis of a three-state model for apical Na channels of frog skin
Publicado: (1990)

Kinetic diversity of Na+ channel bursts in frog skeletal muscle
Publicado: (1989)

Design, Synthesis and Pharmacological Evaluation of New Quinoline-Based Panx-1 Channel Blockers
por: Crocetti, Letizia, et al.
Publicado: (2023)

Pulmonary vasoconstrictor action of KCNQ potassium channel blockers
por: Joshi, Shreena, et al.
Publicado: (2006)

An unusual toxicity with beta blocker and calcium channel blocker
por: Anand, Vijay, et al.
Publicado: (2015)

Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2
por: Cardani, Rosanna, et al.
Publicado: (2013)

The Concise Guide to Pharmacology 2013/14: Ion Channels
por: Alexander, Stephen PH, et al.
Publicado: (2013)

Alteration of STIM1/Orai1-Mediated SOCE in Skeletal Muscle: Impact in Genetic Muscle Diseases and Beyond
por: Conte, Elena, et al.
Publicado: (2021)

Dasatinib/HP-β-CD Inclusion Complex Based Aqueous Formulation as a Promising Tool for the Treatment of Paediatric Neuromuscular Disorders
por: Cutrignelli, Annalisa, et al.
Publicado: (2019)

Transfer of twelve charges is needed to open skeletal muscle Na+ channels
Publicado: (1995)

Systemic Evaluation of Chimeric LNA/2′-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy
por: Christou, Melina, et al.
Publicado: (2020)

Na(v)1.4 Deregulation in Dystrophic Skeletal Muscle Leads to Na(+) Overload and Enhanced Cell Death
por: Hirn, Carole, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_cc5dbs5cimf6u3s7ufkedk2qa0